Search clinical trials for: ACC-001 QS-21

Total 110 results

Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Terminated

A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer Disease

United States
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer Disease

United States
Pfizer
Janssen Alzheimer Immunotherapy (JAI) Research and Development, LLC

Completed

Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer Disease

Spain, France, Germany
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease

Alzheimer's Disease

United States
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Japan
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease

Alzheimer Disease

Japan
University of Kansas Medical Center
Targovax ASA

Not yet recruiting

Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer (TESLA)

Pancreas Cancer

United States
National Cancer Institute (NCI)

Completed

Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype

Follicular Lymphoma | B Cell Lymphoma | Neoplasm

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

Neuroblastoma | High-risk Neuroblastoma | Metastatic Neuroblastoma

United States
Agenus Inc.

Completed

Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes

Herpes Simplex Type 2

United States
Agenus Inc.

Completed

Phase 1a Study to Evaluate Immunogenicity of ASV®

Solid Tumor, Adult

United States
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer Disease

Spain, France, Germany
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Terminated

Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Japan
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

Neuroblastoma

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults

HIV Infections

United States
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease (ACCTION)

Alzheimer's Disease

United States
Synthetic Biologics Inc.

Completed

A Study of the Effect of SYN-010 on Subjects With IBS-C

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
Celgene

Terminated

Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.

Beta Thalassemia Intermedia | Beta Thalassemia Major

France, United Kingdom, Italy, Greece
Université de Montréal
Institut de Recherche Robert-Sauvé en Santé et en Sécurité du Travail

Unknown

Impact of Thermal Stress on Pulmonary Absorption and Toxicokinetics of 3 Organic Solvents

Heat

Canada
National Institutes of Health Clinical Center (CC)

Completed

Nucleic Acid Amplification Testing (NAT) of Blood Donors for HCV and HIV

HIV Infection | Hepatitis C

United States
ACM Biolabs

Completed

Booster Dose Study to Assess the Safety and Immunogenicity of ACM-001 Administered Intramuscularly or Intranasally.

SARS-CoV-2 Infection

Australia
Memorial Sloan Kettering Cancer Center

Completed

Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission

Ovarian Cancer | Peritoneal Cancer | Fallopian Tubes

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Advanced Solid Tumors

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers

Muscle Loss

Canada
Ascendis Pharma A/S

Completed

A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone Deficiency

Adult Growth Hormone Deficiency

Sweden, Denmark, Germany, Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia

Anemia | Myelofibrosis | Myelodysplastic/Myeloproliferative Neoplasm

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.

HIV Infections

United States
Merck Sharp & Dohme LLC

Terminated

Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors

Solid Tumors

United States
Celgene

No longer available

Expanded Access for ACE-011

Myelodysplastic Syndrome

United States
Celgene

Completed

A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis

Anemia | Kidney Failure, Chronic

Belgium, Spain, United Kingdom, Portugal, Germany
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Canada
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Withdrawn

Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women

HIV Infections | HIV Seronegativity
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Completed

A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.

Anemia

United States
Merck Sharp & Dohme LLC

Terminated

Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)

Chemotherapy Induced Anemia

United States, Russian Federation
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women

Osteoporosis

United States
Celgene

Completed

A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma

Multiple Myeloma

Russian Federation
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women

Muscular Atrophy

Canada
Acceleron Pharma, Inc., a wholly-owned subsidiary...

Recruiting

A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12) (SOTERIA)

Pulmonary Arterial Hypertension | PAH

United States, France, Germany, Spain, Sweden, Argentina, Australia, Austria, Colombia, Croatia, Denmark, Greece, Israel, Italy, Korea, Republic of, Netherlands, New Zealand, Portugal, Serbia, Taiwan, United Kingdom, Brazil, Canada, B... and more
Rebecca Silbermann
Celgene

Withdrawn

A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma

Multiple Myeloma

United States
Acceleron Pharma, Inc., a wholly-owned subsidiary...

Recruiting

Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) (HYPERION)

Pulmonary Arterial Hypertension

United States, Belgium, France, Germany, Spain, Argentina, Australia, Austria, Colombia, Croatia, Denmark, Greece, Israel, Korea, Republic of, Netherlands, Portugal, Serbia, Taiwan, Brazil, Canada, Czechia, Italy, New Zealand, Sweden, S... and more
Acceleron Pharma, Inc., a wholly-owned subsidiary...

Active, not recruiting

A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) (ZENITH)

Pulmonary Arterial Hypertension

France, Germany, United States, Australia, Belgium, Canada, Israel, Italy, Mexico, Netherlands, Spain, United Kingdom
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...

United States
Ascendis Pharma Endocrinology Division A/S

Active, not recruiting

A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

Endocrine System Diseases | Adult Growth Hormone Deficiency | Hormone Deficiency

United States, Armenia, Georgia, Greece, Ukraine, Australia, Canada, France, Israel, Italy, Japan, Malaysia, Poland, Romania, Serbia, Slovakia, Spain, Turkey, United Kingdom, Germany, Korea, Republic of
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)

Pulmonary Arterial Hypertension

Japan
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Canada
Merck Sharp & Dohme LLC

Terminated

To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Anemia | Bladder Cancer | Cancer of Head and Neck | Uterine Cervical Cancer | Carcinoma, Small-Cell Lung
Anna Stanhewicz, PhD

Recruiting

Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia

Preeclampsia Postpartum

United States
Ascendis Pharma A/S

Terminated

A Safety, Tolerability and Pharmacokinetics Study of TransCon Treprostinil in Healthy Adult Male Volunteers

Healthy Volunteers

Search clinical trials for: ACC-001 QS-21

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations